Other languages Belite Bio, Inc

Equities

BLTE

US07782B1044

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
40.93 ^USD	+2.97%		+18.71%	-10.54%

26/04	Belite Bio Unveils Plan to Offer 651,380 American Depository Shares	MT
22/03	Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Belite Bio Unveils Plan to Offer 651,380 American Depository Shares	26/04
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan	22/03
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22/03
Belite Bio's Q4 Loss Narrows	12/03
Belite Bio, Inc Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Belite Bio, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Belite Bio Gets Clearance to Launch Tinlarebant Phase 3 Trial for Eye Disease in China	27/12
Belite Bio, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Belite Bio's Q3 Loss Widens	14/11
Belite Bio, Inc. Presents Results from a 24-Month, Phase 2 Study of Tinlarebant in Childhood-Onset Stargardt Disease at the AAO Annual Meeting	06/11
Belite Bio, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga	28/23/28
Belite Bio Completes Enrollment in Phase 3 Trial Assessing Oral Tinlarebant for Stargardt Disease; Shares Rise	24/23/24
Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease	24/23/24
Top Midday Decliners	31/23/31
Sector Update: Health Care Stocks Steady Premarket Wednesday	31/23/31
Top Premarket Decliners	31/23/31
Belite Bio Prices $30 Million Public Offering	31/23/31
Belite Bio Launches Public Offering of American Depositary Shares, Warrants	31/23/31
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Belite Bio, Inc

Equities

BLTE

US07782B1044

Other languages

Filters